On February 11, 2026 Celyad Oncology (Euronext: CYAD) ("Celyad" or the "Company"), reported the acquisition by CellProthera of C-Cathez, the transendocardial catheter originally developed by Celyad Oncology. The acquisition is a decisive step for CellProthera as it prepares to enter Phase 3 clinical trial, with the transendocardial catheter as a cornerstone of its therapeutic approach, enabling targeted delivery of stem cells directly into damaged cardiac tissue. The transaction relates to all intellectual property rights and associated technical documentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, the consideration consists of (i) a purchase price of up to €5 million payable in instalments tied to milestones, and (ii) future royalties on net sales.

The consideration being entirely deferred, the transaction will not impact Celyad Oncology’s current cash runway, which is currently anticipated to extend into Q3-2026

(Press release, Celyad, FEB 11, 2026, View Source [SID1234662611])